Results 31 to 40 of about 9,396,775 (321)

Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in doberman pinschers with preclinical dilated cardiomyopathy (the PROTECT study) [PDF]

, 2012
<p>Background: The benefit of pimobendan in delaying the progression of preclinical dilated cardiomyopathy (DCM) in Dobermans is not reported.</p> <p>Hypothesis: That chronic oral administration of pimobendan to Dobermans with ...
Boswood, A., Braz-Ruivo, L., Culshaw, G.J., Dukes-McEwan, J., Estrada, A., French, A.T., Gordon, S.G., Loureiro, J., O'Grady, M.R., O'Sullivan, M.L., Oyama, M.A., Patteson, M., Smith, A., Summerfield, N.T., Watson, P.J., Willis, R.   +15 more
core   +3 more sources

Most prominent challenges in translational neuroscience and strategic solutions to bridge the gaps: Perspectives from an editorial board interrogation [PDF]

Exploration of Neuroscience
Recent progress in translational neuroscience has significantly advanced our understanding of neurological diseases. Research progress closely went in line with innovations in research methods, which have expanded our insights considerably beyond ...
Dirk M. Hermann, Marco Bacigaluppi, Claudio L. Bassetti, Gabrio Bassotti, Johannes Boltze, Andrew Chan, Turgay Dalkara, Adam Denes, Exuperio Diez-Tejedor, Richard Dodel, Thorsten R. Doeppner, Egor Dzyubenko, Ayman ElAli, Tamas Fulop, Alexander Gerhard, Bernd Giebel, Janine Gronewold, Matthias Gunzer, Thomas Heinbockel, Kaibin Huang, Marcello Iriti, Hans-Otto Karnath, Kasteleijn-Nolst Trenite, Ertugrul Kilic, Giuseppe Lanza, Arthur Liesz, Tim Ullrich Magnus, Jessica Mandrioli, Ayan Mohamud-Yusuf, Thomas Müller, Suyue Pan, Luca Peruzzotti-Jametti, Stefano Pluchino, Ryszard Pluta, Aurel Popa-Wagner, Ameneh Rezayof, Mohamed L. Seghier, Xinhua Shu, Vikram Singh, Jussi Sipilä, Mark Slevin, Yamei Tang, Georgios Tsivgoulis, Giustino Varrassi, Chen Wang, Bayram Yilmaz, Maha S. Zaki, Jinwei Zhang   +47 more
doaj   +1 more source

How Much Evidence Is Enough? Research Sponsor Experiences Seeking Regulatory Acceptance of Digital Health Technology-Derived Endpoints

Digital Biomarkers, 2023
Introduction: Digital health technologies (DHTs) provide opportunities for real-time data collection and assessment of patient function. However, use of DHT-derived endpoints in clinical trials to support medical product labelling claims is limited ...
Brian Perry, Lindsay Kehoe, Teresa Swezey, Quentin Le Masne, Jörg Goldhahn, Alicia Staley, Amy Corneli   +6 more
doaj   +1 more source

Beating the reaction limits of biosensor sensitivity with dynamic tracking of single binding events [PDF]

, 2018
The clinical need for ultrasensitive molecular analysis has motivated the development of several endpoint-assay technologies capable of single-molecule readout.
Sevenler, Derin, Trueb, Jacob, Unlu, M. Selim   +2 more
core   +2 more sources

Clinical characteristics and outcomes of black African heart failure patients with preserved, mid‐range, and reduced ejection fraction: a post hoc analysis of the THESUS‐HF registry

ESC Heart Failure, 2021
Aims Limited data are available on clinical characteristics and prognosis of heart failure (HF) in black African populations especially with respect to current classifications and HF management guidelines.
Anastase Dzudie, Martin Hongieh Abanda, Clovis Nkoke, Blaise Barche, Albertino Damasceno, Christopher Edwards, Beth Davison, Gad Cotter, Karen Sliwa, THEUS‐HF investigators   +9 more
doaj   +1 more source

On the Use of Marker Strategy Design to Detect Predictive Marker Effect in Cancer Immunotherapy [PDF]

, 2019
Indiana University-Purdue University Indianapolis (IUPUI)The marker strategy design (MSGD) has been proposed to assess and validate predictive markers for targeted therapies and immunotherapies.
Han, Yan
core   +1 more source

A potential primary endpoint for clinical trials in glaucoma neuroprotection

Scientific Reports, 2023
The purpose of this retrospective, longitudinal study is to evaluate the relationship between MD slope from visual field tests collected over a short period of time (2 years) and the current United States’ Food and Drug Administration (FDA) recommended ...
Carlos Gustavo De Moraes, Keith J. Lane, Xiao Wang, Jeffrey M. Liebmann   +3 more
doaj   +1 more source

Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial

NeuroImage: Clinical, 2021
Ibudilast (MN-166) is an inhibitor of macrophage migration inhibitory factor (MIF) and phosphodiesterases 3,4,10 and 11 (Gibson et al., 2006; Cho et al., 2010).
Suma Babu, Baileigh G. Hightower, James Chan, Nicole R. Zürcher, Pia Kivisäkk, Chieh-En J. Tseng, Danica L. Sanders, Ashley Robichaud, Haruhiko Banno, Armineuza Evora, Akshata Ashokkumar, Lindsay Pothier, Sabrina Paganoni, Sheena Chew, Joanna Dojillo, Kazuko Matsuda, Mark Gudesblatt, James D. Berry, Merit E. Cudkowicz, Jacob M Hooker, Nazem Atassi   +20 more
doaj   +1 more source

Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model [PDF]

, 2016
Patients with stable coronary artery disease (CAD) constitute a heterogeneous group in which the treatment benefits by angiotensin-converting enzyme (ACE)-inhibitor therapy vary between individuals.
Akkerhuis, KM, Bertrand, ME, Boersma, E, Brugts, JJ, Danser, AHJ, De Maat, M, Ferrari, R, Fox, KM, Oemrawsingh, RM, PERGENE investigators, Redekop, WK, Remme, WJ, Rudez, G, Simoons, ML, Van Vark, LC   +14 more
core   +1 more source

Estimation of causal effects in clinical endpoint bioequivalence studies in the presence of intercurrent events: noncompliance and missing data

Journal of Biopharmaceutical Statistics, 2018
In clinical endpoint bioequivalence (BE) studies, the primary analysis for assessing equivalence between a generic and an innovator product is based on the observed per-protocol (PP) population (usually completers and compliers).
Y. Lou, Michael P. Jones, Wanjie Sun
semanticscholar   +1 more source